Dr. Raj Satkunasivam on Neoadjuvant Sasanlimab and SBRT for Cisplatin-Ineligible MIBC

By Raj Satkunasivam, MD, MS, FRCSC - Last Updated: August 9, 2023

Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, details the RAD VACCINE MIBC trial, a single-arm, phase 2 evaluation of the efficacy and safety of combination neoadjuvant sasanlimab with stereotactic body radiotherapy as an in situ vaccine in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

In his previous comments, Dr. Satkunasivam highlighted traditional treatment approaches for MIBC and the current momentum for an immunotherapy-plus-radiation strategy.

View Dr. Satkunasivam’s previous comments.